アブストラクト
| Title | No.6 末梢神経障害 |
|---|---|
| Subtitle | シリーズ : 抗がん薬治療の副作用 |
| Authors | 名和亜利沙 |
| Authors (kana) | |
| Organization | 公益財団法人がん研究会 がん研有明病院 薬剤部 |
| Journal | 日本臨床腫瘍薬学会雑誌 |
| Volume | 22 |
| Number | |
| Page | 13-22 |
| Year/Month | 2021 / 10 |
| Article | 報告 |
| Publisher | 日本臨床腫瘍薬学会 |
| Abstract | 「はじめに」 がん薬物療法の副作用である化学療法誘発性末梢神経障害(chemotherapy induced peripheral neuropathy: CIPN)は手足のしびれ感や疼痛, 異常な感覚により日常動作に違和感を感じる. CIPNが重症となると, 歩行や衣服の着脱ができなくなるため生活の質(Quality of life: QOL)に大きく影響を及ぼす. 発現率は, 抗がん薬の種類, レジメン, 患者の年齢, 併用薬, 糖尿病や評価する時期により異なり, 30-60%と推測されている. 悪心や骨髄抑制と異なり, 休薬により速やかに回復せず, 回復に月・年単位を要し, 生涯治らないことも稀ではない. がん治療成績向上により, がんによる死亡率は低下しており, 抗がん薬投与後の生存年数が長くなっている. 抗がん薬投与後の副作用が続くことは, その後の生活に大きく影響し, 長期にわたって患者のQOLを低下させる要因となる. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Guido C, Paola M:Chemotherapy-induced peripheral neurotoxicity, Curr Opin Neurol 2015;28(5):500-507.
- 2) Staff NP, Grisold A, Grisold W, Windebank AJ:Chemotherapy-induced peripheral neuropathy:A current review, Ann Neurol 2017;81(6):772-781.
- 3) Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, Andre T:Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer:a pooled analysis of three phase III studies, Ann Oncol 2010;21(4):754-758.
- 4) Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M:Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy:A systematic review and meta-analysis, Pain 2014;155(12):2461-2470.
- 5) 重篤副作用疾患別対応マニュアル 末梢神経障害 厚生労働省;平成21年5月.
残りの38件を表示する
- 6) Flatters SJ, Bennett GJ:Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy:evidence for mitochondrial dysfunction, Pain 2006;122(3):245-257.
- 7) Brewer JR, Morrison G, Dolan ME, Fleming GF:Chemotherapy-induced peripheral neuropathy:Current status and progress, Gynecol Oncol 2016;140(1):176-183.
- 8) Smith JA, Slusher BS, Wozniak KM, Farah MH, Smiyun G, Wilson L, Feinstein S, Jordan MA:Structural Basis for Induction of Peripheral Neuropathy by Microtubule-Targeting Cancer Drugs, Cancer Res 2016;76(17):5115-5123.
- 9) 河野 豊, 他:薬物による神経障害 末梢神経障害の機序, 日本内科学会雑誌, 2007;96:1585-1590.
- 10) 有害事象共通用語規準 v5.0 日本語訳JCOG版(CTCAE v5.0-JCOG) http://www.jcog.jp/doctor/tool/CTCAEv5J_20190905_v22_1.pdf
- 11) NCI-PRO-CTCAE(TM) ITEMS-JAPANESE Item Library Version 1.0 https://healthcaredelivery.cancer.gov/pro-ctcae/pro-ctcae_japanese.pdf
- 12) Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K:Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer, Clin Cancer Res 2005;11(13):4843-4850.
- 13) Lee JJ, Swain SM:Peripheral neuropathy induced by microtubule-stabilizing agents, J Clin Oncol 2006;24(10):1633-1642.
- 14) Mielke S, Sparreboom A, Mross K:Peripheral neuropathy:a persisting challenge in paclitaxel-based regimes, Eur J Cancer 2006;42(1):24-30.
- 15) Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C:Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors:final results of Cancer and Leukemia Group B protocol 9840, J Clin Oncol 2008;26(10):1642-1649.
- 16) Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ:Paclitaxel-induced neuropathy, Ann Oncol 1995;6(5):489-494.
- 17) Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E:Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas, Cancer 1994;73(10):2515-2519.
- 18) Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP:Clinical pattern and associations of oxaliplatin acute neurotoxicity:a prospective study in 170 patients with colorectal cancer, Cancer 2013;119(2):438-444.
- 19) Grothey A:Clinical management of oxaliplatin-associated neurotoxicity, Clin Colorectal Cancer 2005;5(Suppl 1):S38-S46.
- 20) Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP:A review on oxaliplatin-induced peripheral nerve damage, Cancer Treat Rev 2008;34(4):368-377.
- 21) Argyriou AA:Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN), Toxics 2015;3(2):187-197.
- 22) Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A:Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol 2009;27(19):3109-3116.
- 23) Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, Gramont A:OPTIMOX1:a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study, J Clin Oncol 2006;24(3):394-400.
- 24) Ongerboer de Visser BW, Tiessens G:Polyneuropathy induced by cisplatin, Prog Exp Tumor Res 1985;29:190-196.
- 25) Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, Miguel JS:Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma:impact of a dose-modification guideline, Br J Haematol 2009;144(6):895-903.
- 26) Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL:Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomised, phase 3, non-inferiority study, Lancet Oncol 2011;12(5):431-440.
- 27) ヤンセンファーマ:ベルケイド(R) 添付文書 (2019年8月改訂)
- 28) 日本ペインクリニック学会:神経障害性疼痛薬物療法ガイドライン 改訂第2版:真興交易株式会社医書出版部;2016
- 29) 日本がんサポーティブケア学会:がん薬物療法に伴う末梢神経障害マネジメントの手引き 2017年版:金原出版;2017. http://jascc.jp/wp/wp-content/uploads/2018/12/book02.pdf
- 30) Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Smith EML, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL:Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers:ASCO Guideline Update, J Clin Oncol 2020;38(28):3325-3348.
- 31) Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Rhun EL, Preusser M, Scotte F, Taphoorn MJB, Jordan K:Systemic anticancer therapy-induced peripheral and central neurotoxicity:ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up, Ann Oncol 2020;31(10):1306-1319.
- 32) Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL:Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy:a randomized clinical trial, JAMA 2013;309:1359-1367.
- 33) Nihei S, Sato J, Kashiwaba M, Itabashi T, Kudo K, Takahashi K:Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy, Gan To Kagaku Ryoho 2013;40(9):1189-1193.
- 34) Nakashima T, Kiba T, Ogawa Y, Hosokawa A, Shintani H, Okada Y, Taniguchi T, Shigeta M, Kozawa K:A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin, Gan To Kagaku Ryoho 2012;39(9):1443-1445.
- 35) Nakashima T, Kiba T, Ogawa Y, Kimura A, Kido M, Okikawa Y, Ito T, Saito A, Hosokawa A, Shintani H, Okada Y, Taniguchi T, Taniyama K, Kozawa K, Niimi H:A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma, Gan To Kagaku Ryoho 2012;39(5):809-812.
- 36) Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R:Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy:A Randomized Controlled Trial, Clin Drug Investig 2020;40(3):249-257.
- 37) Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y:Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial):a placebo-controlled, double-blind, randomized phase III study, Int J Clin Oncol 2015;20(4):767-775.
- 38) Hoshino N, Ganeko R, Hida K, Sakai Y:Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy:a systematic review and meta-analysis, Int J Clin Oncol 2018;23(3):434-442.
- 39) Kuriyama A, Endo K:Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy:a systematic review and meta-analysis, Support Care Cancer 2018;26(4):1051-1059.
- 40) Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T:Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy:Prospective Self-Controlled Trial, J Natl Cancer Inst 2018;110(2):141-148.
- 41) Beijers AJM, Bonhof CS, Mols F, Ophorst J, de Vos-Geelen J, Jacobs EMG, van de Poll-Franse LV, Vreugdenhil G:Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy, Ann Oncol 2020;31(1):131-136.
- 42) Tsuyuki S, Senda N, Kanng Y, Yamaguchi A, Yoshibayashi H, Kikawa Y, Katakami N, Kato H, Hashimoto T, Okuno T, Yamauchi A, Inamoto T:Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy:a phase II multicenter study by the Kamigata Breast Cancer Study Group, Breast Cancer Res Treat 2016;160(1):61-67.
- 43) Kanbayashi Y, Sakaguchi K, Ishikawa T, Ouchi Y, Nakatsukasa K, Tabuchi Y, Kanehisa F, Hiramatsu M, Takagi R, Yokota I, Katoh N, Taguchi T:Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy:A prospective self-controlled trial, Breast 2020;49:219-224.
